Corbion DATE 23 April 2025 Corbion Q1 2025 Interim Management Statement Corbion announces strong first quarter 2025 result, well on track to deliver full-year outlook Corbion, the Amsterdam-listed sustainable ingredients company that champions preservation through application of science, today publishes its results for Q1 2025 ending 31 March. Key highlights Q1 2025: • Organic sales growth: +7.9% ο Volume/mix: +8.4% ο Price: -0.5% • Sales: € 329.7 million • Adjusted EBITDA: € 54.4 million, an organic increase of +53.9% • Operating profit: € 34.0 million, an organic increase of +186% • FY 2025 outlook affirmed € million Q1 2025 Q1 20241 Total growth Organic growth Sales 329.7 300.4 +9.8% +7.9% Adjusted EBITDA 54.4 34.5 +57.7% +53.9% Adjusted EBITDA margin (%) 16.5% 11.5% Operating Profit 34.0 11.6 +193.1% 186.2% Commenting on today’s results, Olivier Rigaud, CEO, stated: “Corbion had an excellent start to 2025. I am pleased to report on this strong quarter with positive volume/mix and organic Adjusted EBITDA growth, as well as positive free cash flow. Corbion provides essential, natural solutions to meet customers’ preservation and nutrition needs, and the Q1 results highlight the resilience of our businesses. In Functional Ingredients & Solutions, we delivered volume/mix growth in all three businesses (Food, Biochemicals, and Lactic acid to the PLA JV), and we are seeing the results of our efficiency and cost-management measures translating into improved margins to greater than 12%. In Health & Nutrition, we delivered volume/mix growth across all three businesses (Nutrition, Biomedical polymers, and Pharma), with Adjusted EBITDA margins exceeding 30% for the business unit overall. As we navigate the macro-economic and geopolitical uncertainty, we continue to execute on our strategy and remain on track to deliver our 2025 guidance on all forecasted metrics, including volume/mix, Adjusted EBITDA, and free cash flow.” ________________________ 1 Q1 2024 values are presented as continued operations in all tables Attachment 2025-04-23_Corbion_Press release_Q1 2025 View Comments
Corbion announces strong first quarter 2025 results, well on track to deliver full-year outlook
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more
Start Your Free Trial Now!Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...